1. Home
  2. MSEX vs SNDX Comparison

MSEX vs SNDX Comparison

Compare MSEX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSEX
  • SNDX
  • Stock Information
  • Founded
  • MSEX 1897
  • SNDX 2005
  • Country
  • MSEX United States
  • SNDX United States
  • Employees
  • MSEX N/A
  • SNDX N/A
  • Industry
  • MSEX Water Supply
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSEX Utilities
  • SNDX Health Care
  • Exchange
  • MSEX Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • MSEX 1.1B
  • SNDX 1.1B
  • IPO Year
  • MSEX N/A
  • SNDX 2016
  • Fundamental
  • Price
  • MSEX $55.50
  • SNDX $9.24
  • Analyst Decision
  • MSEX Buy
  • SNDX Strong Buy
  • Analyst Count
  • MSEX 4
  • SNDX 10
  • Target Price
  • MSEX $61.00
  • SNDX $35.80
  • AVG Volume (30 Days)
  • MSEX 115.5K
  • SNDX 1.8M
  • Earning Date
  • MSEX 07-30-2025
  • SNDX 07-31-2025
  • Dividend Yield
  • MSEX 2.46%
  • SNDX N/A
  • EPS Growth
  • MSEX 18.33
  • SNDX N/A
  • EPS
  • MSEX 2.40
  • SNDX N/A
  • Revenue
  • MSEX $195,654,000.00
  • SNDX $43,722,000.00
  • Revenue This Year
  • MSEX $9.16
  • SNDX $426.77
  • Revenue Next Year
  • MSEX $7.82
  • SNDX $98.31
  • P/E Ratio
  • MSEX $23.06
  • SNDX N/A
  • Revenue Growth
  • MSEX 16.02
  • SNDX N/A
  • 52 Week Low
  • MSEX $48.18
  • SNDX $8.58
  • 52 Week High
  • MSEX $70.73
  • SNDX $25.07
  • Technical
  • Relative Strength Index (RSI)
  • MSEX 40.12
  • SNDX 44.19
  • Support Level
  • MSEX $53.24
  • SNDX $8.59
  • Resistance Level
  • MSEX $56.65
  • SNDX $9.50
  • Average True Range (ATR)
  • MSEX 1.45
  • SNDX 0.53
  • MACD
  • MSEX 0.02
  • SNDX 0.01
  • Stochastic Oscillator
  • MSEX 28.78
  • SNDX 47.29

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: